Andrea Mogavero

Orbassano, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

Journal: The oncologist

Published: February 11, 2026

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.

Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis.

Journal: Prostate cancer and prostatic diseases

Published: September 04, 2025

A new era for radium-223? Optimizing treatment by balancing efficacy and toxicity through combination therapies.

A new era for radium-223? Optimizing treatment by balancing efficacy and toxicity through combination therapies.

Journal: Critical reviews in oncology/hematology

Published: May 16, 2025

The evolving landscape of stage III unresectable non-small cell lung cancer "between lights and shadows".

The evolving landscape of stage III unresectable non-small cell lung cancer "between lights and shadows".

Journal: Cancer treatment reviews

Published: January 17, 2025

From Cancer to Immune Organoids: Innovative Preclinical Models to Dissect the Crosstalk between Cancer Cells and the Tumor Microenvironment.

From Cancer to Immune Organoids: Innovative Preclinical Models to Dissect the Crosstalk between Cancer Cells and the Tumor Microenvironment.

Journal: International journal of molecular sciences

Published: September 14, 2024

First-line immunotherapy in non-small cell lung cancer: how to select and where to go.

First-line immunotherapy in non-small cell lung cancer: how to select and where to go.

Journal: Expert review of respiratory medicine

Published: January 31, 2024

Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group.

Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group.

Journal: JAMA network open

Published: November 06, 2023

Assessing the role of colonic and other anatomical sites uptake by [18 F]FDG-PET/CT and immune-inflammatory peripheral blood indexes in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors.

Assessing the role of colonic and other anatomical sites uptake by [18 F]FDG-PET/CT and immune-inflammatory peripheral blood indexes in patients with advanced non-small cell lung cancer treated with first-line immune checkpoint inhibitors.

Journal: Thoracic cancer

Published: May 16, 2023

Deciphering Lung Adenocarcinoma Heterogeneity: An Overview of Pathological and Clinical Features of Rare Subtypes.

Deciphering Lung Adenocarcinoma Heterogeneity: An Overview of Pathological and Clinical Features of Rare Subtypes.

Journal: Life (Basel, Switzerland)

Published: March 29, 2023

Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.

Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: September 25, 2020

Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects.

Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects.

Journal: Oncogene

Published: June 06, 2012

Showing 1-11 of 11

Last Updated: 09/26/2026